What’s next for VEGF? ASCO offered clues, but answers will have to wait

Not long ago, there were hopes that a new class of cancer drugs would repeat the success of Keytruda. Instead, it seems more likely they could end up making up for its weaknesses. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing…

Source: Endpoints News